Alkermes announces plan to initiate second clinical trial of ALKS 7119
Alkermes announced preliminary findings from a phase 1 clinical trial of ALKS 7119, an oral, novel small molecule that acts on multiple key receptor systems in the brain. ALKS 7119 is being developed for the treatment of agitation in patients with Alzheimer’s disease. April 28, 2016